Implantable penile prostheses (IPPs) are an established treatment option for erectile dysfunction (ED), and are covered by insurance in about 80% of cases, reports a paper in the September issue of Urology Practice®, an Official Journal of the American Urological Association (AUA).
Johnson & Johnson picks Onco360 as partner for LAZCLUZE
LAZCLUZE has received FDA approval based on positive outcomes from the Phase III MARIPOSA study in non-small cell lung cancer patients. Credit: New Africa/Shutterstock. Johnson